



GENMAB A/S SUMMONS ANNUAL GENERAL MEETING

Summary: Genmab to hold Annual General Meeting on April 15, 2009.

Copenhagen, Denmark; March 25, 2009 – Genmab A/S (OMX: GEN) summons the Annual General Meeting on Wednesday April 15, 2009 at 2:00 pm CEST at the Radisson SAS Scandinavia Hotel, Amager Boulevard 70, 2300 Copenhagen S, Denmark.

Agenda:

1. Report of the Board of Directors on the Company's activities during the year.
2. Presentation of the audited Annual Report 2008 for approval and the discharge of the Board of Directors and the Management.
3. Decision as to the settlement of loss according to the approved Annual Report.

The Board of Directors proposes that the year's loss of DKK 772 million be carried forward by transfer to accumulated deficit.

4. Election of members of the Board of Directors.

Pursuant to Article 12 of the Company's Articles of Association, the members of the Board of Directors are elected for periods of three years. The election period for Dr. Ernst Schweizer and Hans Henrik Munch-Jensen expires at the General Meeting. The Board of Directors proposes to re-elect Hans Henrik Munch-Jensen for a three year period.

About Hans Henrik Munch-Jensen

Mr. Munch-Jensen is Director at Prospect where he advises listed companies in relation to strategic and financial communication. Previously, Mr. Munch-Jensen was Executive Vice President, CFO of H. Lundbeck A/S from 1998 to 2007, where he was responsible for overseeing the company's finance and investor relations activities. He previously served as a politics and finance columnist for the newspaper Dagbladet Børsen and as Vice President of the Copenhagen Stock Exchange. He was a member of various Lundbeck boards as well as the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of Vækstforum, Region Hovedstaden. Mr. Munch-Jensen received his master in Political Science from the University of Aarhus.

GENMAB A/S SUMMONS ANNUAL GENERAL MEETING

It is the opinion of the Board of Directors that Hans Henrik Munch-Jensen is independent.

5. Election of auditor.

The Board of Directors proposes re-election of PricewaterhouseCoopers Statsautoriseret Revisionsaktieselskab A/S as the Company's elected auditor.

6. Proposals from the Board of Directors and/or the shareholders:

(a) All warrants granted under the Company's warrant programmes from 1999–2003 pursuant to Article 5 of the Articles of Association have been exercised or have lapsed as non exercised on April 1, 2009. Consequently, the Board of Directors proposes that Schedule B is removed from the Articles.

(b) The Board of Directors proposes that VP Investor Services A/S' address "Helgeshøj Allé 61, P.O. Box 20, 2630 Taastrup" in Article 6 of the Articles of Association is replaced with "Weidekampsgade 14, 2300 Copenhagen S".

(c) The Board of Directors proposes that the name "OMX The Nordic Exchange Copenhagen" in Article 8 of the Articles of Association is replaced with "NASDAQ OMX Copenhagen".

7. Miscellaneous.

Adoption of the proposals under item 6 (a) to 6 (c) of the agenda to amend the Articles of Association requires that each such proposal is adopted by an affirmative vote of not less than 2/3 of the votes cast as well as of the voting share capital represented at the Annual General Meeting.

The Company's share capital amounts to DKK 44,906,042 divided into shares of DKK 1 each or any multiple hereof. Each share amount of DKK 1 shall entitle the shareholder to one vote.

No later than 8 days before the Annual General Meeting the agenda, the complete proposals as well as the Annual Report will be made available to the Company's shareholders at the Company's offices at Bredgade 34, 1260 Copenhagen K, Denmark. The documents are also available at the Company's website, www.genmab.com.

Admission card/proxy: Any shareholder is entitled to attend the Annual General Meeting after having submitted a request for an admission card no later than Tuesday April 14, 2009 at 10:00 AM CEST. Admission cards may be requested by contacting VP Investor Services A/S, telephone +45 43 58 88 66 or fax +45 43 58 88 67. Alternatively via www.genmab.com or www.uk.vp.dk/agm.

GENMAB A/S SUMMONS ANNUAL GENERAL MEETING

Shareholders who do not expect to be able to participate in the General Meeting may grant proxy to the Board of Directors or to a person appointed by the shareholder. A form for submitting votes by proxy may be obtained via www.genmab.com. The shareholders exercise their financial rights through their own deposit banks, cf. Section 73,5(2) of the Danish Public Companies Act.

Any shareholder, to whom admission card already has been issued, but who is prevented from attending the Annual General Meeting is kindly asked to notify the company - preferably before Tuesday April 14, 2009.

Copenhagen, March 25, 2009
On behalf of the Board of Directors

MICHAEL B. WIDMER
Chairman

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™]; HuMax-TF[™]; HuMax-Her2[™]; HuMax-VEGF[™] and UniBody[®] are all trademarks of Genmab A/S. Arzerra[™] is a trademark of GlaxoSmithKline.

Contact: Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com

###